Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Sacituzumab govitecan-hziy |
| Trade Name | Trodelvy |
| Synonyms | IMMU-132|Sactizumab|Sacituzumab govitecan |
| Drug Descriptions |
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate (ADC) composed of a monoclonal anti-TROP2 antibody linked to the active metabolite of irinotecan (SN-38), which binds to TROP2-positive cancer cells and induces DNA breakage and apoptosis (PMID: 26541586). Trodelvy (sacituzumab govitecan-hziy) is FDA-approved for use in patients with metastatic triple-negative breast cancer (TNBC) who have received two or more prior therapies, in patients with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies, as first-line therapy for patients with unresectable locally advanced or metastatic TNBC, and in combination with Keytruda (pembrolizumab) as first-line treatment for patients with unresectable locally advanced or metastatic TNBC whose tumors express CD274 (PD-L1, CPS >/= 10) (FDA.gov). |
| DrugClasses | TROP2 Antibody 19 |
| CAS Registry Number | 1491917-83-9 |
| NCIT ID | C102783 |